Activin receptor-like kinase family (ALK family)

The Activin receptor-like kinase (ALK) family, also known as the Type I TGF-beta superfamily receptors, consists of seven transmembrane serine/threonine kinases (ALK1 through ALK7). These receptors are essential components of the signaling complexes for ligands in the TGF-beta superfamily, including TGF-betas, activins, and bone morphogenetic proteins (BMPs). Upon ligand binding to a Type II receptor, the Type I receptor is recruited and phosphorylated, which then activates downstream SMAD proteins to regulate gene transcription. This pathway plays a critical role in diverse biological processes such as cell proliferation, differentiation, apoptosis, and angiogenesis. Dysregulation of ALK signaling is implicated in various diseases, including cancer progression, tissue fibrosis, and rare genetic disorders like Fibrodysplasia Ossificans Progressiva (FOP) and Hereditary Hemorrhagic Telangiectasia (HHT). Therapeutic strategies targeting these receptors include small molecule kinase inhibitors and ligand traps, though challenges remain regarding isoform selectivity and potential off-target toxicities related to the widespread physiological roles of these receptors.

Other names

Activin receptor-like kinase familyALK familyType I TGF-beta superfamily receptorsActivin-like kinasesALK1-7ACVRL1ACVR1BMPR1AACVR1BTGFBR1BMPR1BACVR1C

Inhibition of serine/threonine kinase activity or ligand sequestration to prevent receptor activation and downstream SMAD signaling.